News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
274,087 Results
Type
Article (14288)
Company Profile (106)
Press Release (259685)
Multimedia
Podcasts (66)
Webinars (13)
Section
Business (88302)
Career Advice (467)
Deals (15396)
Drug Delivery (73)
Drug Development (36724)
Employer Resources (50)
FDA (6388)
Job Trends (6247)
News (150754)
Policy (14130)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (444)
Accelerated approval (14)
Adcomms (8)
Allergies (71)
Alliances (23328)
ALS (56)
Alzheimer's disease (479)
Antibody-drug conjugate (ADC) (102)
Approvals (6577)
Artificial intelligence (205)
Autoimmune disease (47)
Automation (13)
Bankruptcy (150)
Best Places to Work (4381)
BIOSECURE Act (9)
Biosimilars (120)
Biotechnology (40)
Bladder cancer (38)
Brain cancer (30)
Breast cancer (174)
Cancer (1335)
Cardiovascular disease (154)
Career advice (419)
Career pathing (14)
CAR-T (51)
CDC (6)
Cell therapy (158)
Cervical cancer (9)
Clinical research (32041)
Collaboration (743)
Compensation (329)
Complete response letters (34)
COVID-19 (779)
CRISPR (46)
C-suite (452)
Cystic fibrosis (58)
Data (1843)
Denatured (18)
Depression (45)
Diabetes (127)
Diagnostics (1385)
Digital health (10)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (120)
Drug pricing (114)
Drug shortages (12)
Duchenne muscular dystrophy (82)
Earnings (33512)
Editorial (21)
Employer branding (4)
Employer resources (46)
Events (39014)
Executive appointments (539)
FDA (7492)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (440)
Gene editing (74)
Generative AI (18)
Gene therapy (169)
GLP-1 (444)
Government (1406)
Grass and pollen (4)
Guidances (164)
Healthcare (3579)
HIV (12)
Huntington's disease (9)
IgA nephropathy (39)
Immunology and inflammation (69)
Immuno-oncology (15)
Indications (55)
Infectious disease (846)
Inflammatory bowel disease (74)
Inflation Reduction Act (7)
Influenza (25)
Intellectual property (115)
Interviews (60)
IPO (5914)
IRA (33)
Job creations (2055)
Job search strategy (374)
JPM (29)
Kidney cancer (9)
Labor market (28)
Layoffs (205)
Leadership (8)
Legal (3449)
Liver cancer (22)
Longevity (8)
Lung cancer (184)
Lymphoma (124)
Machine learning (13)
Management (17)
Manufacturing (420)
MASH (70)
Medical device (1303)
Medtech (1310)
Mergers & acquisitions (9907)
Metabolic disorders (444)
Multiple sclerosis (48)
NASH (14)
Neurodegenerative disease (83)
Neuropsychiatric disorders (38)
Neuroscience (894)
Neurotech (1)
NextGen: Class of 2026 (1588)
Non-profit (603)
Now hiring (21)
Obesity (231)
Opinion (142)
Ovarian cancer (39)
Pain (110)
Pancreatic cancer (52)
Parkinson's disease (80)
Partnered (11)
Patents (224)
Patient recruitment (121)
Peanut (12)
People (29787)
Pharmaceutical (64)
Pharmacy benefit managers (18)
Phase 1 (8312)
Phase 2 (13527)
Phase 3 (12215)
Pipeline (1977)
Policy (135)
Postmarket research (1401)
Preclinical (3343)
Press Release (25)
Prostate cancer (86)
Psychedelics (17)
Radiopharmaceuticals (136)
Rare diseases (358)
Real estate (2661)
Recruiting (19)
Regulatory (10974)
Reports (15)
Research institute (575)
Resumes & cover letters (55)
Rett syndrome (5)
RNA editing (6)
RSV (20)
Schizophrenia (69)
Series A (81)
Series B (53)
Service/supplier (2)
Sickle cell disease (47)
Special edition (10)
Spinal muscular atrophy (81)
Sponsored (9)
Startups (1647)
State (2)
Stomach cancer (5)
Supply chain (49)
Tariffs (68)
The Weekly (46)
Vaccines (238)
Venture capital (33)
Weight loss (143)
Women's health (28)
Worklife (4)
Date
Last 7 days (212)
Last 30 days (665)
Last 365 days (10390)
2026 (1166)
2025 (10721)
2024 (12508)
2023 (14250)
2022 (19568)
2021 (20080)
2020 (19038)
2019 (14891)
2018 (11714)
2017 (13889)
2016 (13130)
2015 (15474)
2014 (12419)
2013 (10592)
2012 (11397)
2011 (11923)
2010 (10889)
Location
Africa (318)
Alabama (19)
Alaska (1)
Arizona (78)
Arkansas (3)
Asia (20908)
Australia (2689)
California (3213)
Canada (1500)
China (561)
Colorado (147)
Connecticut (134)
Delaware (126)
Europe (40912)
Florida (612)
Georgia (63)
Hawaii (1)
Idaho (10)
Illinois (354)
India (45)
Indiana (242)
Iowa (2)
Japan (251)
Kansas (77)
Kentucky (20)
Louisiana (4)
Maine (2)
Maryland (426)
Massachusetts (2627)
Michigan (46)
Minnesota (168)
Mississippi (1)
Missouri (33)
Montana (8)
Nebraska (7)
Nevada (16)
New Hampshire (8)
New Jersey (1416)
New Mexico (7)
New York (914)
North Carolina (628)
North Dakota (2)
Northern California (1462)
Ohio (82)
Oklahoma (5)
Oregon (18)
Pennsylvania (726)
Puerto Rico (13)
Rhode Island (17)
South America (508)
South Carolina (10)
Southern California (1404)
Tennessee (53)
Texas (458)
United States (12830)
Utah (67)
Virginia (161)
Washington D.C. (44)
Washington State (225)
West Virginia (1)
Wisconsin (39)
Wyoming (1)
274,087 Results for "recursion pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Recursion Downsizes by 20% To Boost Cash Position
As of March 31, Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to last into the fourth quarter of 2027.
June 10, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update
November 5, 2025
·
15 min read
Press Releases
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals
July 9, 2025
·
5 min read
Press Releases
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update
August 6, 2025
·
16 min read
Press Releases
Recursion to Participate in Upcoming Investor Conference
April 1, 2025
·
1 min read
Press Releases
Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program
September 4, 2025
·
4 min read
Biotech Bay
Helix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic Data
Helix, a leading population genomics company and provider of precision medicine genomics solutions, announced a groundbreaking multi-year agreement with Recursion Pharmaceuticals, a leading clinical-stage TechBio company decoding biology to industrialize drug discovery.
June 24, 2024
·
2 min read
Neuroscience
Recursion Reports Thin Mid-Stage Efficacy Data for Rare Brain Disease Therapy
Recursion’s oral drug candidate for cerebral cavernous malformation showed no improvements in patient- or physician-reported outcomes at 12 months. The biotech will engage with the FDA to determine the need for an additional study.
September 4, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Recursion Reports First Quarter 2025 Financial Results and Provides Business Update
May 5, 2025
·
20 min read
Press Releases
Angle PLC Announces Agreement with Recursion Pharmaceuticals
September 19, 2024
·
2 min read
1 of 27,409
Next
